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Accepted 31 January 2013AbstractObjective: To investigate the perinatal outcomes of women who suffered from thrombocytopenia at delivery but did not have other diseases
during pregnancy.
Materials and Methods: We considered all singleton deliveries after 24 weeks of gestation at Chang Gung Memorial Hospital, Taipei, Taiwan
between 2001 and 2010. Women were excluded from this study if they suffered from any of the following conditions: chronic hypertension,
hepatitis, acute fatty liver, liver cirrhosis, nephropathy, overt diabetes mellitus, connective tissue disease, systemic lupus erythematosus, or
immune thrombocytopenia. Pregnancies complicated by gestational hypertension, preeclampsia, or fetal anomalies during gestation were also
excluded. A total of 18,384 deliveries were included for analysis. Women were divided into three groups according to platelet count at
admission.
Results: A total of 787 pregnancies (4.3%) were complicated by thrombocytopenia. Thrombocytopenic women had a significantly higher rate of
cesarean delivery compared to women who did not have this condition. No other differences were observed among these three groups regarding
the rates of adverse pregnancy outcomes.
Conclusions: The results indicate that women who suffered from incidental thrombocytopenia at delivery but did not have other diseases during
pregnancy were not at increased risk for adverse pregnancy outcomes.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Thrombocytopenia, defined as a platelet count of
<150  109/L, is a common hematologic abnormality during
pregnancy, with an incidence of 6.6% [1]. When thrombocy-
topenia is detected during pregnancy, it may be related to a
preexisting underlying disease, such as bone marrow disease,
hypersplenism, or congenital platelet disorder. It may also be a
sign of complex clinical disorders that are unique to preg-
nancy, such as preeclampsia and hemolysis, elevated liver* Corresponding author. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital at Taipei, 199 Dunhua North Road, Songshan Dis-
trict, Taipei City, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2013.01.025enzymes, and low platelet count (HELLP) syndrome.
Furthermore, autoimmune diseases, including systemic lupus
erythematosus, antiphospholipid syndrome, thrombotic
thrombocytopenic purpuraehemolytic uremic syndrome, and
immune thrombocytopenia (ITP) may relapse or be first
detected during pregnancy. Nevertheless, the most common
cause of pregnancy-related thrombocytopenia is gestational
thrombocytopenia, which is diagnosed through exclusion
when the postpartum platelet count returns to normal and is
usually associated with an uneventful pregnancy outcome.
Although a number of these pregnancy related conditions
may cause morbidity or even death if not treated promptly,
most instances of thrombocytopenia are benign. Severe
neonatal thrombocytopenia is infrequent; however, the
incidence varies according to the causes of maternalcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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thrombocytopenic pregnancies effectively if the underlying
cause of the condition is diagnosed prior to or at the time of
delivery; however, for many obstetric patients, a definitive
diagnosis of thrombocytopenia is only made after delivery.
This situation presents a challenge for clinicians when
establishing a safe plan for delivery. In many pregnancies, a
low platelet count is first discovered during a complete blood
cell count prior to delivery. Thus, we conducted a prospective
study to evaluate maternal complications and neonatal out-
comes for healthy women who had incidental thrombocyto-
penia with uncertain diagnosis prior to delivery.
Materials and methods
Data for this study were obtained from the computerized
obstetrics database of Chang Gung Memorial Hospital, Taipei,
Taiwan. Data included demographic characteristics, medical
and obstetric history, the course of the current pregnancy, and
perinatal outcome. Information in the database was collected
from daily medical and delivery records by trained personnel.
In a number of cases, a postpartum interview was conducted to
collect additional information. Data were routinely reviewed at
weekly departmental meetings. Details related to the organi-
zation of the database have previously been reported [4].
Informed consent was not required because we disconnected
personal information from clinical data. This study was
approved by the Institutional Review Board of Chang Gung
Memorial Hospital (No. 101-3416B).
In Taiwan, elective termination of pregnancy is permitted
prior to 24 weeks of gestation. Therefore, we considered all
singleton deliveries after 24 weeks of gestation between 2001
and 2010. Women were excluded if they suffered from chronic
hypertension, overt diabetes mellitus, liver diseases (acute
hepatitis, acute fatty liver, and liver cirrhosis), renal diseases,
and autoimmune disorders such as systemic lupus erythema-
tosus and ITP. Pregnancies complicated by fetal structural or
chromosomal anomalies and gestational hypertensive diseases
including preeclampsia, eclampsia, and HELLP syndrome
were also excluded. After omitting pregnancies that did not
meet study criteria, a total of 18,384 deliveries were included
for analysis.Table 1
Characteristics of the study population.
Variables Group 1 (n ¼ 29)a
Age (y) 32 (27e33)
Gestational age (wk) 39 (38e39)
Platelet count ( 109/L) 87 (81e92)
Prepregnant BMI (kg/m2) 20.0 (18.5e22.8)
Primiparity 12 (41.4)
Conception assisted by reproductive technology 1 (3.4)
Previous history of abortion 13 (44.8)
Previous history of fetal death 1 (3.4)
Epidural analgesia 15 (51.7)
Data are presented as median (interquartile range) or n (%).
BMI ¼ body mass index.
a Group 1: Women with a platelet count of <100  109/L; b Group 2: Women
Women with a platelet count of >150  109/L; d The p values are based on FishUpon admission to the labor floor, all women underwent
a complete blood count, as part of routine laboratory testing.
Women with a platelet count of <150  109/L but who did
not suffer from the aforementioned diseases were deemed to
have incidental thrombocytopenia. These individuals were
divided into three groups according to platelet count:
Group 1: platelet count <100  109/L; Group 2: platelet
count 100e150  109/L; and Group 3: platelet count
150  109/L.
We studied the following perinatal outcomes: postpartum
hemorrhage (defined as a blood loss >500 mL in vaginal de-
liveries and >1000 mL in cesarean deliveries), disseminate
intravascular coagulopathy (defined as platelet count
<100  109/L, decreased fibrinogen, and elevated D-dimer
and fibrin degradation products), placental abruption, cesarean
delivery, peripartum hysterectomy, birth weight, fetal death,
intrapartum fetal distress, 1-minute and 5-minute Apgar scores
<7, admission to the neonatal intensive care unit, and neonatal
death.
The following maternal characteristics were evaluated as
potential confounding factors in assessing the relationship
between maternal platelet count and pregnancy outcome: age
of mother, gestational age, parity, prepregnant body mass
index (BMI, kg/m2), conception method (natural or assisted by
reproductive technology), previous fetal deaths, previous
abortions, and usage of epidural analgesia.
Statistical analysis was performed using SPSS version 20
(SPSS Inc., Chicago, IL, USA). Nominal variables were
expressed by count and percentage. Nominal variables were
analyzed using Chi-square tests or Fisher’s exact test, and
posthoc testing with the Bonferroni correction. Normality was
tested using the KolmogoroveSmirnov test. All measurement
variables had nonparametric distribution and were expressed
by median (interquartile range). Finally, the KruskaleWallis
test was conducted followed by Dunn’s posthoc test. A p value
<0.05 was considered statistically significant.
Results
Among the 18,384 deliveries included in this study, 787
(4.3%) were complicated by thrombocytopenia. The charac-
teristics of the study population are outlined in Table 1. ThereGroup 2 (n ¼ 758)b Group 3 (n ¼ 17,597)c pd
31 (28e34) 31 (29e34) 0.880
39 (38e40) 39 (38e40) 0.626
135 (122e143) 236 (203e272) <0.001
20.0 (18.8e21.6) 20.5 (19.1e22.4) <0.001
423 (55.8) 9578 (54.4) 0.278
9 (1.2) 176 (1.0) 0.231
278 (36.7) 6029 (34.3) 0.194
6 (0.8) 172 (1.0) 0.310
537 (70.8) 12,357 (70.2) 0.087
with a platelet count between 100  109/L and 150  109/L; c Group 3:
er’s exact test or KruskaleWallis test.
Table 2
Perinatal outcomes of women with thrombocytopenia.
Group 1 (n ¼ 29) Group 2 (n ¼ 758) Group 3 (n ¼ 17,597) Pc
Postpartum hemorrhage 0 6 (0.79) 178 (1.01) 0.783
Disseminated intravascular coagulopathy 1 (3.4) 0 10 (0.1) 0.026
Placental abruption 1 (3.4) 9 (1.2) 190 (1.1) 0.282
Cesarean section 13 (44.8) 286 (37.7) 5823 (33.1) 0.012
Peripartum hysterectomy 0 0 5 (0.03) 1.000
Birth weight (g) 3210 (2910e3585) 3190 (2930e3485) 3185 (2925e3450) 0.611
Fetal death 1 (3.4) 3 (0.4) 59 (0.3) 0.085
Intrapartum fetal distress 1 (3.6) 21 (2.8) 417 (2.4) 0.445
1-min Apgar score <7a 0 11 (1.5) 288 (1.6) 0.926
5-min Apgar score <7a 0 2 (0.3) 39 (0.2) 0.705
Admission to neonatal intensive care unitb 0 54 (7.2) 1113 (6.4) 0.295
Neonatal deathb 0 0 14 (0.1) 1.000
Data are expressed as median (interquartile range) or n (%).
a Sixty-five cases were excluded, including 2 cases of precipitate labor with deliveries prior to arrival at the hospital and 63 cases of fetal death; b Sixty-
three cases of fetal death were excluded; c The p values are based on Fisher’s exact test or KruskaleWallis test.
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Group 3. No differences were observed in the medians of
maternal age, gestational age at delivery, parity, rate of
conception using assisted reproductive technology, previous
fetal death, previous abortion, or administration of epidural
analgesia. The prepregnant BMI of women in Group 2 was
significantly lower than that of women in Group 3 (20.0 kg/m2
vs. 20.5 kg/m2, p < 0.001). Women in Group 1 also had a
lower prepregnant BMI (20.0 kg/m2) compared to those in
Group 3, but the difference was not statistically significant.
Table 2 summarizes the prevalence of adverse perinatal
outcomes for each group. No differences were observed in the
rates of postpartum hemorrhage, peripartum hysterectomy, or
placental abruption among the three groups. Women in Group
2 had a significantly higher frequency of cesarean delivery
compared to those in Group 3 (37.7% vs. 33.1%, p ¼ 0.008).
Women in Group 1 had a higher frequency of cesarean de-
livery (44.8%) than those in Groups 2 and 3; however, these
differences were not statistically significant.
Sixty-three women who suffered fetal death were
excluded in risk analysis of neonatal death or admission to
the neonatal intensive care unit. These 63 women, as well as
two individuals who delivered prior to arrival at the hospital,
were excluded in risk analysis of low Apgar scores and
intrapartum fetal distress. Among the mothers included in
analysis, no significant difference was observed in the risk of
intrapartum fetal distress, fetal death, low Apgar scores,
admission to the neonatal intensive care unit, or neonatal
death.
Discussion
In our study, the prevalence of thrombocytopenia was 4.3%,
which was lower than that of a previous study [1]. This vari-
ance might be due to our exclusion of women with major
systemic diseases as well as those with gestational hyperten-
sive diseases. In this study, women with thrombocytopenia had
a lower prepregnant BMI compared to those with a normal
platelet count; however, we were unable to determine whetherlower platelet counts were correlated with lower BMI scores.
Several previous reports found that obese women have
significantly higher platelet counts than women in the normal
range [5,6], although the significance was attenuated following
adjustment for inflammatory markers. Obesity is a chronic
inflammatory state; thus the elevated platelet count may be
related to this subclinical inflammation [7,8]. Furthermore,
interleukin-6, which originates primarily from adipose tissue,
has been identified as playing a crucial role in stimulating
megakaryocytopoiesis [9,10].
In this study, women with thrombocytopenia had a higher
rate of cesarean delivery than women with a normal platelet
count. Thrombocytopenia is not usually considered an indi-
cation of cesarean delivery and most previous studies have
preferred vaginal delivery, as long as no other obstetric in-
dications were present. Nevertheless, clinicians may still be
concerned about obstetric complications, such as vaginal he-
matoma or vaginal wall laceration, which can lead to uncon-
trolled bleeding when exacerbated by thrombocytopenia.
Therefore, when thrombocytopenic women present signs of
abnormal labor, clinicians may aggressively suggest cesarean
section, which increases the incidence. However, our results
show that women who had thrombocytopenia at delivery but
did not suffer from any other medical diseases had perinatal
outcomes similar to those with a normal platelet count. The
influence of a higher cesarean rate on maternal outcome was
undetermined.
In one pregnancy complicated by placental abruption,
disseminated intravascular coagulation, and intrauterine fetal
death, the mother had a platelet count below 10  109/L. This
case suggests that clinicians should exclude occult placental
abruption and acute blood loss when investigating the cause of
severe thrombocytopenia in a woman without a major medical
disease or gestational hypertensive disorder. However, the risk
of postpartum hemorrhage, hysterectomy, and placental
abruption in women with thrombocytopenia was not elevated,
compared with that of normal women. Furthermore, no
women in Group 1 or Group 2 suffered postpartum hemor-
rhage or underwent hysterectomy.
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nant woman is gestational thrombocytopenia. Typically,
gestational thrombocytopenia includes mild asymptomatic
thrombocytopenia with platelet counts >70  109/L. Patients
generally have no prior history of thrombocytopenia and the
condition resolves spontaneously following delivery [1,11].
Gestational thrombocytopenia is a benign condition, usually
detected incidentally during the third trimester and presents no
risk of increased bleeding to the mother. The risk of throm-
bocytopenia in neonates born to mothers with gestational
thrombocytopenia is also considered negligible [11e13].
Although the etiology of this condition is unknown, many
features of gestational thrombocytopenia are similar to those
of mild ITP. Moreover, several observations support the hy-
pothesis that gestational thrombocytopenia may be a mild and
transient form of ITP [14,15].
In contrast to gestational thrombocytopenia, ITP occurs in
one out of every 1000 pregnancies, accounting for only 3% of
the cases of pregnancy-related thrombocytopenia [1,11,16].
Differentiating ITP from gestational thrombocytopenia may be
less important for the mother, because mild thrombocytopenia
does not threaten maternal health [17]. For the fetus, however,
a definite diagnosis is important because maternal ITP causes
severe neonatal thrombocytopenia in 9e15% of all cases.
Furthermore, the risk of neonatal intracranial hemorrhage, a
rare condition unrelated to method of delivery [2], is between
1% and 2% in cases of maternal ITP; gestational thrombo-
cytopenia does not pose this risk [15,18]. According to pre-
vious studies on ITP, neonatal platelet counts at birth do not
correlate with maternal platelet counts at delivery
[3,11,13,19]. However, severe maternal ITP may increase the
risk of neonatal thrombocytopenia. Factors that are suspected
to increase the risk of neonatal thrombocytopenia include the
following: maternal history of splenectomy [19], maternal
platelet count of <50  109/L at some point during the
pregnancy [2,20], and a previous birth complicated by
neonatal thrombocytopenia [3,20]. In pregnancies complicated
by ITP, it is advisable to monitor neonatal thrombocytopenia
for several days because neonatal platelet counts are often
undiscovered until 1e2 days after delivery [2,18].
According to this study, pregnancies with thrombocyto-
penia do not face an increased risk of intrapartum fetal
distress, intrauterine fetal death, low Apgar scores, admission
to the neonatal intensive care unit, or neonatal death. This
study excluded women with immune thrombocytopenia;
therefore, we assumed that most mothers suffering from
thrombocytopenia in our study were likely to have gestational
thrombocytopenia. Only one woman, who suffered from
placenta previa, had a platelet count below 70  109/L. After
receiving a platelet transfusion, she delivered by cesarean
section. Although the platelet count of this mother increased
after delivery, she still presented mild thrombocytopenia.
This study has several limitations. First, the sample sizes of
thrombocytopenic groups were small, particularly that of the
group with severe thrombocytopenia. Thus, statistical results
of pregnancy outcomes should be interpreted with caution.Second, the methods of managing pregnancies with incidental
thrombocytopenia were heterogeneous over our study period
of 10 years. We did not investigate the treatment of every
thrombocytopenic woman; therefore, the effects of different
treatment methods on the perinatal outcomes of women with
thrombocytopenia were not determined.
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